Ciphergen expands collaboration with Pfizer

Published: 28-Jan-2003

Ciphergen Biosystems has expanded its collaboration with Pfizer to include studies designed to discover protein biomarkers from human serum that provide early detection of chronic obstructive pulmonary disease (COPD).


Ciphergen Biosystems has expanded its collaboration with Pfizer to include studies designed to discover protein biomarkers from human serum that provide early detection of chronic obstructive pulmonary disease (COPD).

These studies will be conducted at Ciphergen's Biomarker Discovery Center in Copenhagen on behalf of the Experimental Medicine Group at Pfizer France.

'We're delighted that Pfizer has charged us with applying our ProteinChip Systems and Biomarker Discovery Center scientists to discover protein biomarkers for COPD,' said William E. Rich, president and ceo of Ciphergen. 'We believe this further demonstrates interest in our technology as an enabling tool for protein-based predictive medicine.'

In October 2001, Ciphergen entered into a collaboration with Pfizer designed to discover proteins in serum in pre-clinical models as well as to evaluate the relative importance and utility of such proteins as biomarkers associated with drug safety. This work initially focused on the issue of vasculitis toxicity.

You may also like